-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Sq3ZcqWMRNQ8K6bDexhdKCXzQFRmFvpnJL+WMWFQ6TvzT+VWVhK6U5K/i3K2klcm TDd9zfQPRFOQAgRoED9WvA== 0000933745-05-000044.txt : 20050823 0000933745-05-000044.hdr.sgml : 20050823 20050823153613 ACCESSION NUMBER: 0000933745-05-000044 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050817 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050823 DATE AS OF CHANGE: 20050823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MIRAVANT MEDICAL TECHNOLOGIES CENTRAL INDEX KEY: 0000933745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770222872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-25544 FILM NUMBER: 051043663 BUSINESS ADDRESS: STREET 1: 336 BOLLAY DRIVE CITY: SANTA BARBARA STATE: CA ZIP: 93117 BUSINESS PHONE: 8056859880 MAIL ADDRESS: STREET 1: 336 BOLLAY DRIVE CITY: SANTA BARBARA STATE: CA ZIP: 93117 FORMER COMPANY: FORMER CONFORMED NAME: PDT INC /DE/ DATE OF NAME CHANGE: 19941214 8-K 1 form8kaug2005sutcliffe.htm FORM 8-K AUGUST 23, 2005 Form 8-K August 23, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 17, 2005

MIRAVANT MEDICAL TECHNOLOGIES
(Exact name of registrant as specified in its charter)

DELAWARE
  
0-25544
  
77-0222872
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer
Identification No.)

7408 Hollister Avenue
Santa Barbara, CA 93117
(Address of principal executive offices, including zip code)

(805) 685-9880
(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





 
 
Item 1.01 Entry into a Material Definitive Agreement.
 
On August 17, 2005, Miravant Medical Technologies (the “Company”) entered into a consulting arrangement with Robert J. Sutcliffe, the Company’s current Chairman of the Board of Directors. Pursuant to the consulting arrangement, Mr. Sutcliffe is expected to advise and assist the Company on its strategic initiatives, including without limitation, fundraising and corporate partnering and licensing activities. The initial term of the consulting arrangement will run through December 31, 2005. Mr. Sutcliffe will receive compensation in the amount of $125,000 payable in two installments of $62,500 on August 17, 2005 and October 17, 2005. The arrangement is subject to renewal for periods beginning on January 1, 2006 at the option of the Board of Directors of the Company. Mr. Sutcliffe will continue his other regular duties as Chairman of the Board of Directors.
 
    A copy of the consulting agreement between the Company and Mr. Sutcliffe will be included in the Company's next Form 10-Q quarterly report.

 
Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.
 
None





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
MIRAVANT MEDICAL TECHNOLOGIES
     
 
By:
/s/ John M. Philpott
  
   
John M. Philpott
Chief Financial Officer

Date: August 23, 2005
 -----END PRIVACY-ENHANCED MESSAGE-----